Introduction
Diabetes is a chronic metabolic disorder and rapidly increasing worldwide in both developed and developing countries [1, 2] . The global prevalence of diabetes in 2000was 2.8% representing 171 million people worldwide and it was predicted to rise up to 4.4% representing 366 million people for 2030 [3] . However, recent diabetes statistics has shown that the worldwide prevalence of diabetes in 2014 was 8.3%representing 387 million people which are even higher than the predication for 2030. Further, this number is projected to increase by another 205 million people in series of non-enzymatic complex reactions between reducing sugars and proteins which lead to generate multitude of glycation end products [5] [6] [7] [8] .
It is scientifically well proven that formation and accumulation of glycation products especially advanced glycation end products (AGEs) play a vital role in the development and progression of deleterious diabetes complications. Thus, glycation inhibitors and glycation reversing agents offer a potential strategy as therapeutics for management of diabetes and its complications [5] [6] [7] [8] . Natural products have been used in the management of diabetes since ancient times. Fenugreek (Trigonella foenum-graecum) is an annual plant which belongs to the family Leguminosae is one of the oldest spice thought the world [9] [10] [11] . Fenugreek seed is well known for various medicinal properties including anti-diabetic properties world over [9] [10] [11] . The anti-diabetic properties of fenugreek seed have been shown in both in vitro and in vivo models covering various modes of actions [9] [10] [11] . However, the effect of fenugreek seed extracts on anti-glycation activity is limitedly studied. Further, there are no previous reports on effect of fenugreek seed extracts on glycation reversing ability which is one of the most important aspects in the management of diabetes complications. Therefore, this study investigated anti-glycation and glycation reversing ability of fenugreek seed extract.
Materials and Methods

Fenugreek Seed Sample and Preparation of Extract
Fenugreek seeds purchased from local market were used in this study. Seventeen grams of fenugreek seed flour was extracted in 200mL of 70% ethanol-water (v/v). The extraction was carried out for 16 h at room temperature (30±2ºC) at 150rpm using an orbital shaker. The sample was then centrifuged at 3500 rpm for 5min and the resulting supernatant was evaporated using a rotary evaporator with low pressure at 45ºC and freeze dried.
Chemicals and Reagents
Bovine serum albumin (BSA), D-glucose, Trolox, 1,1-diphenyl-2-picrylhydrazine (DPPH),2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), 2,4,6-tripyridyl-s-triazine (TPTZ), potassium persulfate, gallic acid, trichloroacetic acid (TCA) and Folin-Ciocalteu phenol reagentwere purchased from SigmaAldrich, USA. All the other chemicals used for the preparation of buffers and solvents were of analytical grade.
Anti-Glycation Activity
The anti-glycation activity of fenugreek seed extract was performed according to the method of Matsuura et al. [12] . With some modifications, Reaction volume of 1 mL containing 800 µg BSA, 400 mM glucose and fenugreek seed extract (12.5, 25, 50, 100, 200, 400 µg/mL; n=3) in 50 mM phosphate buffer (pH 7.4) containing 0.02% sodium azide (w/v) were incubated at 60 ºC for 40 h. Then, 600 µL of each sample were transferred to 1.5 mL eppendorf tubes and added with 60 µL of 100% (w/v) TCA. Samples were then centrifuged at 15,000 rpm at 4 ºC for 4 min and the supernatants were removed. The resulting AGEs (advanced glycation end-products)-BSA precipitate was dissolved in 3 mL of phosphate buffer saline (pH 10) and fluorescence intensity was measured at an excitation wave length of 370 nm and emission wave length of 440 nm using a 96-well florescence micro plate reader (SPECTRA max-Gemini EM, Molecular Devices Inc, USA). Rutin was used as the standard (positive control). Anti-glycation activity (inhibition %) of fenugreek seed extract and rutin was calculated using the following equation.
Where, F c is the florescence of incubated BSA and glucose (control), F b is the florescence of incubated BSA alone (blank), Fs is the florescence of the incubated BSA, glucose and fenugreek seed extract or the positive control and F sb is the florescence of incubated BSA with the fenugreek seed extractor the positive control.
Glycation Reversing Ability
The glycation reversing ability of fenugreek seed extract was performed according to the method of Premakumara et al [13] . with some modifications. Reaction volume of 1 mL containing 800 µg BSA and 400 mM glucose in 50 mM phosphate buffer (pH 7.4) containing 0.02% sodium aside (w/v) was incubated at 60 ºC for 40 h. Then, aliquots of 600 µL were transferred to 1.5 mL eppendorf tubes and 60 µL of 100% (w/v) TCA was added. Samples were then centrifuged (15,000 rpm) at 4 ºC for 4 min and the supernatants were removed. The resulting AGEs-BSA precipitates were dissolved in 50 mM phosphate buffer (pH 7.4) and added with 75, 150, 300, 600 µg/mL fenugreek seed extract (n=3) in a final reaction volume of 1 mL for incubation at 60 ºC for 40 h. After cooling, 60 µL of 100% (w/v) TCA was added, stirred and centrifuged (15,000 rpm) at 4 ºC for 4 min. The resulting precipitates were dissolved in 3 mL of phosphate buffer saline (pH 10) and the fluorescence intensity was measured at an excitation wave length of 370 nm and emission wave length of 440 nm using a96-well florescence micro plate reader (SPECTRA max-Gemini EM, Molecular Devices Inc, USA). Percentage glycation reversing was calculated using the following equation.
Where, F c is the florescence of incubated BSA and glucose (control), F b is the florescence of incubated BSA alone (blank), Fs is the florescence of the incubated BSA, glucose and fenugreek seed extract and F sb is the florescence of incubated BSA with the fenugreek seed extract.
Antioxidant Properties
Total Polyphenolic Content: The Total polyphenolic content (TPC) of fenugreek seed extract was determined according to the method of Singleton et al [14] . Using 96-well micro-plates (n=3). Twenty micro liters of fenugreek seed extract (1 mg/mL) was added to 110 µL of ten times diluted freshly prepared Folin-Ciocalteu reagent. Then, 70 µLof sodium carbonate solutions was added and incubated at room temperature (25±2 oC) for 30 min. The absorbance readings were taken at 765 nm using a 96 well micro plate reader (Spectra Max Plus 384 , Molecular Devices, USA). Gallic acid was used to construct the standard curve. TPC was expressed as mg gallic acid equivalents (GAE)/g of fenugreek seed extract.
Total Flavonoid Content:
Total flavonoid content (TFC) of fenugreek seed extract was determined according to the method of Siddhuraju and Becker [15] . Using 96-well micro-plate (n=3). Twenty five μL of 1 mg/mL fenugreek seed extract and 75 µL of methanol were added and pre plate reading was taken at 415 nm. Then, 100 μL of 20% aluminum chloride solution was added and incubated at room temperature (30±2oC) for 10 min. The absorbance readings were taken at 415 nm using a 96 well micro plate reader. Quercetin was used to construct the standard curve. TFC was expressed as mg quercetin equivalents (QE)/g of fenugreek seed extract.
Ferric Reducing Antioxidant Power: Ferric reducing antioxidant power (FRAP) of fenugreek seed extract was performed according to the method of Benzie and Szeto [16] . with some modifications in 96 well micro plates (n=3). The working FRAP reagent was prepared by mixing 300 mM acetate buffer (pH 3.6), 10 mM TPTZ solution and 20 mM FeCl 3 .6H 2 O in a ratio of 10:1:1. Then the mixture was incubated at 37 oC for 10 min in a shaking water bath. The TPTZ solution was prepared by making a solution of 10 mM TPTZ in 40 mM HCl. A reaction volume of 200 μL, containing 150 μL of working FRAP reagent, 25 μL acetate buffer and 25μL (1 mg/mL) of fenugreek extract were incubated at room temperature (25±2 oC) for 8 min. The absorbance readings were then taken at 600 nm using a 96 well micro plate reader. Trolox was used to construct the standard curve. Results were expressed as mg Trolox equivalents (TE)/g of fenugreek seed extract.
DPPH Radical Scavenging Activity:
The DPPH radical scavenging activity of fenugreek seed extract was performed according to the method described by Blois [17] . In 96-well microplates (n=3). A reaction volume of 200 μL, containing 125 μM of DPPH radical, fenugreek seed extract (25, 50, 100, 200, 400, 800 µg/mL; n=3) and methanol were incubated at 25±2 oC for 10 min. Then, absorbance readings were taken at 517 nm using a 96 well micro plate reader. Trolox was used as the standard. DPPH radical scavenging activity (inhibition %) of fenugreek seed extract and Trolox were calculated using the following equation. Results were expressed as % inhibition, IC 50 values and mg Trolox equivalents/g fenugreek seed extract. 
ABTS Radical Scavenging Activity:
The ABTS radical scavenging activity of fenugreek seed extract was determined according to the method described by Re et al [18] . In 96-well micro-plates (n=3). A stable stock solution of ABTS radical was produced by reacting 7.8 mM of ABTS in potassium persulphate at 37 oC for 16 h in dark condition. A reaction volume of 200 μL, containing 40 μL of seven times diluted ABTS stock solution, 150 μL phosphate buffer and different concentrations of fenugreek seed extract (6.25, 12.5, 25, 50, 100, 200 µg/mL; n=3) were incubated at 25±2 oC for 10 min. Then, absorbance values were recorded at 734 nm using a 96 well micro plate reader. Trolox was used as the standard antioxidant. ABTS radical scavenging activity (inhibition %) of fenugreek seed extract and Trolox were calculated using the following equation. Results were expressed as % inhibition, IC50 values and mg Trolox equivalents/g fenugreek seed extract. Where, A c is the absorbance of the control and A s is the absorbance of the fenugreek seed extract.
Statistical Analysis
Data of each experiment were statistically analyzed using SAS version 6.12. One way analysis of variance (ANOVA) and the Duncan's Multiple Range Test (DMRT) were used to determine the differences among treatment means.
Results
Anti-Glycation Activity
Anti-glycation activity of fenugreek seed extract is given in 
Glycation Reversing Activity
Glycation reversing activity of fenugreek seed extract is given in Table 2 . Fenugreek seed extract showed dose dependent glycation reversing activity with an EC 50 of 553.37±8.02µg/mL. Results are presented as mean ± SE (n=3).
Antioxidant Properties
Data on antioxidant activities of fenugreek seed extract is summarized in Table 3 . As shown, fenugreek seed extract had considerable in vitro antioxidant activity in tested antioxidant assay models. Data represented as mean ± SE. TPC: mg gallic acid equivalents/g of extract (n=3); TFC: mg quercetin equivalents/g of extract (n=3); FRAP: mg trolox equivalents/g of extract (n=4); ABTS: mg Trolox equivalents/g of extract (n=3); DPPH: mg Trolox equivalents/g of extract (n=3). 
Discussion
This study examined the potential of fenugreek seed extract on inhibition of protein glycation, ability to reverse glycated end products and antioxidant potential in vitro. Investigations were carried out using well established, widely used, validated, reproducible, sensitive and reliable bioassays in vitro [12] [13] [14] [15] [16] [17] [18] [19] . BSAglucose glycation model was used since it is more relevant to the biological system of human [20] . Fenugreek seed extract was used as it is claimed to have anti-diabetic properties in the Sri Lankan traditional system of medicine [21] . and folklore. Further, there are numerous studies on anti-diabetic properties of fenugreek seed vitro and in vivo models and also in clinical studies [11] . However, protein glycation inhibitory activity of fenugreek seed is limitedly investigated. Further, glycation reversing ability of fenugreek seed is not reported to date.
The results of the present study demonstrated that fenugreek seed extract had both anti-glycation (IC 50 147.99±3.94 µg/mL) and glycation reversing (EC 50 553.37±8.02 µg/mL) activities. The ability of fenugreek seed extract to inhibit protein glycation was moderate compared to the reference drug rutin (6.7 fold low). Some previous studies have also confirmed the anti-glycation activity of fenugreek seed [22] . A study carried out by Moniruzzaman et al [22] . Had reported the anti-glycation activity (IC 50 values) of water and ethanolic extracts of fenugreek seed were > 200 and 121.125 µg/ mL respectively. Further, some clinical investigations have reported that both seed and leaf extracts of fenugreek can significantly reduce the glycated hemoglobin levels [11] . However, there are no previous reports on glycation reversing potential of fenugreek seed. Present study is the first study to report the presence of both anti-glycation and glycation reversing activities in fenugreek seed. Thus, findings indicate the potential use of fenugreek seed in ameliorating various diabetes complications [8, 23] .
Oxidative stress and protein glycation is closely related and tightly linked under hyperglycemic conditions in diabetic patients [20, 24] . Several studies have shown that oxidative stress increases the rate of formation of advanced glycation end products. AGEs have the propensity to generate reactive oxygen species and further accelerate the protein glycation under hyperglycemic conditions in diabetic patients [6, 20, 24] . Thus, combat of oxidative stress is one of the therapeutic approaches in treating diabetic patients [24] . It is reported that AGEs associated pathologies of diabetes complications can be treated effectively using synergistic action of compounds offering both anti-glycation and antioxidant properties [24, 25] . In the present study seed extract of fenugreek had antioxidant activity via radical scavenging (ABTS & DPPH: 35.45±0.32 and 28.13±0.76 mg Trolox equivalents/g extract respectively) and reducing power (21.06±0.42 Trolox equivalents/g extract). Previous studies have reported seed extract of fenugreek had antioxidant activity via multiple mechanisms and such mechanisms include radical scavenging, reducing power, inhibition of lipid per oxidation, carbonyl trapping and metal ion chelation [26, 27] .
Anti-glycation activity of natural products including spices and condiments has strong correlation with antioxidant activity [24, 28] . Therefore observed anti-glycation activity o fenugreek seed extract in the present study may be at least partly due to its anti-oxidant activity. In contrast polyphenols a group of secondary metabolites with diversified phytochemical classes such as flavones, flavanones, flavones, is flavones and proanthocyanidins. These compounds are reported to have anti glycation activity in several in vitro and in vivo studies [20, 28] . Polyphenols reported to exert anti-glycation activity through multiple mechanisms such mechanisms include radical scavenging, carbonyl trapping, metal iron chelation, protein interaction and blocking the receptor for advanced glycation end products (RAGE) [20, 25] . Fenugreek seed extract in the present study had total phenolics (43.67±2.85 mg Gallic acid equivalents/g extract) particularly as flavonoids (25.25±0.91mg quercetin equivalents/g extract). It is reported that among various classes of polyphenolic dietary flavonoids possesses the highest potential for the inhibition of glycoxidation with strong antioxidant activity [20] . Considering all, it can be hypothesized that observed anti-glycation and glycation reversing ability of seed extract of fenugreek may be at least partly due to its polyphenolis exerting antioxidant properties. Interestingly, this is the first study to report glycation reversing ability of seed extract of fenugreek and indicates its potential in managing AGEs associated pathologies in diabetes patients.
Conclusion
It is concluded that seed extract of fenugreek had both antiglycation and glycation reversing activities in BSA-glucose glycation model. Interestingly, glycation reversing activity of fenugreek seed is a novel finding for the anti-diabetic properties of fenugreek and indicates potential use in managing advanced glycation end products associated pathologies in diabetic patients.
